NICE Chairman, Sharmila Nebhrajani, today announced Professor Jonathan Benger CBE as incoming chief executive, with effect from Friday 19 December 2025 taking over from Dr Samantha Roberts.
Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma TA1113 3 December 2025 3 December 2025 Talquetamab for treating relapsed and refractory ...
Suggested remit: To appraise the clinical and cost effectiveness of givinostat within its marketing authorisation for treating Duchenne muscular dystrophy in people 6 years and over. Anticipate the ...
Evidence-based recommendations on dostarlimab (Jemperli) with platinum-containing chemotherapy for primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair ...
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma
Isatuximab, plus pomalidomide and dexamethasone, is recommended for use within the Cancer Drugs Fund as an option for treating relapsed and refractory multiple myeloma in adults who have had ...
Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) British National Formulary for Children (BNFC) Life sciences Library and knowledge services What ...
This guideline covers management of acne vulgaris in primary and specialist care. It includes advice on topical and oral treatments (including antibiotics and retinoids), treatment using physical ...
This guideline covers the care of pregnant women and pregnant trans and non-binary people and their babies during labour and immediately after birth. It focuses on women and pregnant people who give ...
The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...
Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) British National Formulary for Children (BNFC) Life sciences Library and knowledge services What ...
This guideline has been updated and replaced by NICE rapid guideline on managing COVID-19 (NG191) ...
The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback